Braveheart Bio Reports Third-Quarter 2026 Financial Results
Braveheart Bio reported its third-quarter 2026 financial results. The supplied body is truncated and provides no figures.
Story updates
09:03:59 PM UTC
SquawkNews
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential diffe
09:07:43 PM UTC
SquawkNews
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimenLIONHEART-HCM oHCM Phase 3 enrolling with interim analysis expected in second half of 2027; TRUEHEART…
09:08:07 PM UTC
SquawkNews
Braveheart Bio reported a third-quarter 2026 net loss of $26.5M, or $0.51 per share, versus a $59.1M loss, or $10.05 per share, in the prior-year quarter. Cash, cash equivalents and investments were $503.5M, and runway is expected into 2029.Material DetailsContext by AI AnalystThe results show a cl…